Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Better Therapeutics Inc BTTX

Healthcare Biotechnology
Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company, which is engaged in developing a software-based novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases (CMDx). Its platform allows for the creation of multiple PDTs that are designed to treat patients with CBT, delivered digitally via an app, to address the underlying causes of CMDx. Its lead PDT product candidate, AspyreRx, is a digital behavioral therapeutic delivering CBT for the treatment of a cardiometabolic disease. AspyreRx is a prescription-only digital treatment indicated to provide cognitive behavioral therapy to patients 18 years or older with T2D. The device targets behavior to aid in the treatment of T2D. Its pipeline also includes programs for the treatment of hypertension, hyperlipidemia, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Dysfunction-Associated Steatohepatitis (MASH) and chronic kidney disease.


GREY:BTTX - Post by User

Better Therapeutics Inc > BTTX ....heres another paid Pump...like LQR & PCSA
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(69)
•••
Post by Iseneschalon Oct 16, 2023 9:55am
62 Views
Post# 35685135

BTTX ....heres another paid Pump...like LQR & PCSA

BTTX ....heres another paid Pump...like LQR & PCSAThese guys have Zero morals

They are paid to lay you out with high priced paper
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities